APDN earnings

STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers

STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, August 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402Inter

STONY BROOK, NY / ACCESSWIRE / February 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2024 financial results after market close on Thursday, February 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, February 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-940

- Conference Call/Webcast Scheduled for Today at 4:30 PM ET -STONY BROOK, NY / ACCESSWIRE / December 7, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its fourth quarter ended September 30, 2023."Our fiscal fourth quarter concludes a productive year during which we took a number of critical steps that place us firmly in the execution phase of our pivot to a biotherapeutic manufacturing-first growth strategy," stated Dr. James A. Hayward, president and CEO of Applied DNA. "We closed on the strategic acquisition of Spindle Biotech that empowered the launch of our Linea™

STONY BROOK, NY / ACCESSWIRE / December 5, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and full year financial results 2023 ended September 30, 2023, on Thursday, December 7, 2023, after the market close. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. ET.Date & Time: Thursday, December 7 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers (toll free): 866-605-3852Live webcast: https://event.choru

Conference Call/Webcast Scheduled for Today at 4:30 PM ETSTONY BROOK, NY / ACCESSWIRE / August 10, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for the third quarter of fiscal 2023 ended June 30, 2023."Our fiscal third quarter performance stands out for the substantial progress made to advance the development and commercialization of our LinearDNA™ platform for biotherapeutic applications that culminated shortly after the close of the quarter with our acquisition of Spindle Biotech and launch of our Linea™ IVT platform for mRNA production," stated Dr. James A. Hayward,

STONY BROOK, NY / ACCESSWIRE / August 7, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended June 30, 2023 after the market close on Thursday, August 10, 2023. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. ET.Date & Time: Thursday, August 10 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers (toll free): 866-605-3852Live webcast: https://event.choruscall.com/mediaframe/webcast

- linearDNA™ Gaining Momentum as a Differentiated DNA Template for mRNA Production, Company Identifies Early Development-Stage Acquisition Target to Potentially Expand Commercial Advantages -- Balance of CY23 Set Up for Multiple Value Inflection Points -- Conference Call/Webcast Scheduled for Today at 4:30 PM ET -STONY BROOK, NY / ACCESSWIRE / May 11, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for the second quarter of fiscal 2023 ended March 31, 2023.Commenting on the Company's quarterly performance, Dr. James A. Hayward, president and CEO, stated, "We made steady pr

Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended March 31, 2023 after the market close on Thursday, May 11, 2023. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. ET. Date & Time: Thursday, May 11 @ 4:30 p.m. ET Dial In: Domestic callers (toll free): 844-887-9402 Canadian callers (toll free): 866-605-3852 International callers: 412-317-6798 Live webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=MRM611FN A

- Total Revenues of $5.3 Million, Up 48% Over FQ4 2022 and 26% Over FQ1 2022, 72% and 74% Reduction in Operating Loss, Respectively - - Included Orders for R&D Quantities of linearDNA™ from New Biopharma Customers - - Maintains Timeline to cGMP Capacity, Initiates Build-out of Cost-Efficient Facility - - Business Update Conference Call/Webcast Scheduled for Today at 4:30 PM ET - Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for the first quarter of fiscal 2023, ended December 31, 2022. "Applied DNA delivered a solid start to the fiscal year with sequential and year-over-y

Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction ("PCR")-based technologies, today announced that it will release financial results for the three months ended December 31, 2022, after the market closes on Thursday, February 9, 2023. The Company will host a conference call for the investment community to discuss its results and answer questions at 4:30 p.m. ET. Date & Time: Thursday, February 9 @ 4:30 p.m. ET Dial In (ask to be joined into the Applied DNA Sciences call): Domestic callers (toll free): 844-887-9402 Canadian callers (toll free): 866-605-3852 International callers: 412-317-6798 Live webcast: https://event.

Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that it plans to release its fiscal 2022 fourth quarter and year-end financial results after the market close on Wednesday, December 14, 2022. The Company's management will host a conference call with investors and covering analysts starting at 4:30 pm ET that same day. On the call, Chief Financial Officer Beth Jantzen and President and CEO Dr. James A. Hayward will discuss the Company's quarterly financial performance and recent accomplishments, followed by a question-and-answer session. To access the conference call: U.S. callers should dial 1-844-887-9402, and internation

Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction ("PCR")-based technologies, today announced that Dr. James A. Hayward, president and CEO, and Beth Jantzen, chief financial officer, will host a conference call and webcast on Thursday, August 11, 2022, at 4:30 p.m. ET to provide financial results and corporate updates for the fiscal third quarter of 2022. To access the conference call: U.S. callers should dial 1-844-887-9402, and international callers should dial +1-412-317-6798 approximately five minutes before the call begins. Participants should ask to be connected to the Applied DNA Earnings Conference Call. The confe

Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in cell-free, enzymatic DNA production, today announced that it will report fiscal 2022 second quarter financial results after market close on Thursday, May 12, 2022. The Company's management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘Company Events' sub-page of the Company's Investor Relations website and embedded into the live webcast. Conference Call and Webcast Information - Live Date: Thursday, May 12, 2022, at 4:30 p.m. Eastern Time   Dial in: 844-887-9402 412-317-6

- Revenues of $4.2 Million Increased 158% Year-over-Year and 37% Sequentially - - Momentum Continues into FQ2 with January Revenues of Approximately $2.0 Million - - Company to Hold Conference Call and Webcast Today, Thursday, February 10, 2022, at 4:30 PM ET - Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the first quarter of fiscal 2022, ended December 31, 2021. "Applied DNA had an excellent start to fiscal 2022 as we continued to capitalize on the demand for enterprise-scale COVID-19 testing while making meaningful pro

Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report fiscal 2022 first quarter financial results after market close on Thursday, February 10, 2022. The Company's management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘Company Events' sub-page of the Company's Investor Relations website and embedded into the live webcast. Conference Call and Webcast Information - Live Date:       Thursday, February 10, 2022, at 4:30

- FQ4 Revenues of $3.0 Million, Up 868% Over FQ4'20 and Up 79% Over FQ3'21 - - Record Full-Year Revenues of $9.0 Million, up 367% Over Fiscal 2020 - - Company Submits Linea™ 2.0 COVID-19 Validation Package to New York State Department of Health - - Company to Hold Conference Call and Webcast Today, Thursday, December 9, 2021, at 4:30 PM ET - Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the full fiscal year and quarter ended September 30, 2021. "We are pleased to report a fourth consecutive quarter of year-over-year reve

Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report its fourth quarter and full fiscal year 2021 financial results after market close on Thursday, December 9, 2021. The Company's management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘Company Events' sub-page of the Company's Investor Relations website and embedded into the live webcast. Conference Call and Webcast Information - Live   Date: Thursday, Dece

Revenues Increased 294% Year-Over-Year to $1.7 Million – Year-To-Date Revenues Increase 270% From Last Fiscal Year to $6.0 Million – - Company to Hold Conference Call and Webcast Today, Thursday, August 12, 2021, at 4:30 PM ET - Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the three and nine months ended June 30, 2021. "We delivered excellent year-over-year revenue growth in the fiscal third quarter while laying the groundwork to secure a recently awarded COVID-19 testing services contract that has potential to be the l

Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report fiscal 2021 third quarter financial results after market close on Thursday, August 12, 2021. The Company's management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. EDT that same day. Presentation slides will also be posted to the ‘IR Calendar and Corporate Presentations' sub-page of the Company's corporate website and embedded into the live webcast. Conference Call and Webcast Information - Live Date: Thursday, August 12, 2021,

- Full Service, Turnkey Solution Anchored by Applied DNA Clinical Labs' safeCircle™ Pooled COVID-19 Testing to Be Deployed Across All 25 CUNY Campuses to Facilitate Fall Re-Opening – - Company to Report Fiscal Third Quarter Financial Results and Hold Investor Conference Call on Thursday, August 12, 2021 - Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that its wholly-owned subsidiary, Applied DNA Clinical Labs, LLC, (ADCL) was awarded a competitively-bid COVID-19 testing contract by the City University of New York (CUNY) Board of Trustees to